Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -56.27% is 166% below its 5-year average of -21.15%, near the low end of its 5-year range (-56.27%–19.82%).
48.16% below its 12-month average of -37.98%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -14.76%.
RETURN ON ASSETS (ROA)
-56.27%
RETURN ON ASSETS (ROA) AVG TTM
-37.98%
RETURN ON ASSETS (ROA) AVG 3Y
-21.94%
RETURN ON ASSETS (ROA) AVG 5Y
-21.15%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-48.16%
CURRENT VS 3Y AVG
-156.44%
CURRENT VS 5Y AVG
-166.05%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-26.90%
median of 504 covered companies
CURRENT VS SECTOR MEDIAN
-109.18%
vs the sector median at left
Cullinan Therapeutics, Inc.
Market Cap
$985.79M
Return on Assets (ROA)
-56.27%
TTM Avg
-37.98%
3Y Avg
-21.94%
5Y Avg
-21.15%
Market Cap
$989.05M
Return on Assets (ROA)
-13.12%
TTM Avg
-18.77%
3Y Avg
-18.48%
5Y Avg
-18.48%
Market Cap
$992.79M
Return on Assets (ROA)
-23.69%
TTM Avg
-98.11%
3Y Avg
-69.18%
5Y Avg
-69.18%
Market Cap
$1.01B
Return on Assets (ROA)
-10.18%
TTM Avg
-8.89%
3Y Avg
-12.61%
5Y Avg
-16.81%
Market Cap
$943.26M
Return on Assets (ROA)
-39.67%
TTM Avg
-22.62%
3Y Avg
-34.56%
5Y Avg
-34.56%
Market Cap
$942.78M
Return on Assets (ROA)
-50.49%
TTM Avg
-30.32%
3Y Avg
-31.10%
5Y Avg
-27.11%
Market Cap
$1.03B
Return on Assets (ROA)
-0.20%
TTM Avg
-7.25%
3Y Avg
-2.02%
5Y Avg
0.01%
Market Cap
$1.04B
Return on Assets (ROA)
-43.17%
TTM Avg
-16.38%
3Y Avg
-11.13%
5Y Avg
-30.16%
Market Cap
$922.50M
Return on Assets (ROA)
55.85%
TTM Avg
-44.25%
3Y Avg
-43.62%
5Y Avg
-43.05%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | $985.79M | -56.27% | -37.98% | -21.94% | -21.15% |
| Aktis Oncology, Inc. (AKTS)vs › | $989.05M | -13.12% | -18.77% | -18.48% | -18.48% |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $992.79M | -23.69% | -98.11% | -69.18% | -69.18% |
| Janux Therapeutics, Inc. (JANX)vs › | $1.01B | -10.18% | -8.89% | -12.61% | -16.81% |
| CeriBell, Inc. (CBLL)vs › | $943.26M | -39.67% | -22.62% | -34.56% | -34.56% |
| Kura Oncology, Inc. (KURA)vs › | $942.78M | -50.49% | -30.32% | -31.10% | -27.11% |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.03B | -0.20% | -7.25% | -2.02% | 0.01% |
| Immatics N.V. (IMTX)vs › | $1.04B | -43.17% | -16.38% | -11.13% | -30.16% |
| Arbutus Biopharma Corp (ABUS)vs › | $922.50M | 55.85% | -44.25% | -43.62% | -43.05% |
| HealthStream, Inc. (HSTM)vs › | $921.45M | 4.06% | 3.72% | 3.23% | 2.82% |
ROA
-56.3%
ROE
-63.6%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -49.04% |
| 2024-12-31 | -26.92% |
| 2023-12-31 | -31.63% |
| 2022-12-31 | 19.82% |
| 2021-12-31 | -15.00% |
| 2020-12-31 | -24.13% |
| 2019-12-31 | -19.95% |
| 2018-12-31 | -40.96% |
